Clinical Trial Update: Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of Kymriah (tisagenlecleucel) in adults with refractory or relapsed follicular lymphoma; results have been post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Kymriah (tisagenlecleucel)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Follicular Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2022-07-22